164,335 Shares in Ironwood Pharmaceuticals, Inc. $IRWD Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd purchased a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the fourth quarter, Holdings Channel reports. The firm purchased 164,335 shares of the biotechnology company’s stock, valued at approximately $554,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IRWD. Bank of America Corp DE lifted its stake in Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after purchasing an additional 8,337,672 shares in the last quarter. Millennium Management LLC lifted its stake in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. AQR Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 144.3% in the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares in the last quarter. Marshall Wace LLP lifted its stake in Ironwood Pharmaceuticals by 616.3% in the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 3,436,036 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Ironwood Pharmaceuticals by 740.5% in the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IRWD shares. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 price objective on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Citizens Jmp boosted their price objective on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $3.35 on Thursday. The firm has a market cap of $546.25 million, a PE ratio of 5.58 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a one year low of $0.61 and a one year high of $5.78. The firm’s 50 day moving average price is $3.82 and its 200-day moving average price is $3.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $106.51 million during the quarter, compared to analysts’ expectations of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. Equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the sale, the director owned 9,188,635 shares of the company’s stock, valued at $28,025,336.75. The trade was a 42.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.30% of the stock is currently owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.